drugset
drugset / Trial / NCT04338126

Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients

NCT04338126 ↗

Phase 2 Withdrawn University of Alabama at Birmingham
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

Timeline

Start
2021-09-30
Primary completion
2021-12-15
Completion
2021-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Due to ongoing vaccination efforts, feasibility for recruitment is low”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 mg/kg Oral
Subject Tranexamic Acid Small molecule 1300 mg Oral

Indications

COVID-19